In melanoma, the EZH2 gain in benign melanocytic lesions has been shown to promote the loss of PCs, to enhance pro-tumorigenic Wnt/β-catenin signaling, and to drive metastatic processes. This evidence concerns the gene EZH2 and melanoma.